KIDRON NADAV 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Oramed (ORMP) CEO Nadav Kidron Receives RSU Award
What Happened
Nadav Kidron, President, CEO and a director of Oramed Pharmaceuticals (ORMP), received a grant of 167,005 restricted stock units (RSUs) on March 17, 2026. The Form 4 reports the award at $0.00 per unit (the filing shows $0 total), since this is an equity grant rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-03-17; Form 4 filed 2026-03-18 (Accession 0001213900-26-031013).
- Grant: 167,005 RSUs reported at $0.00 per unit (award, code A).
- Vesting: RSUs vest ratably in 8 quarterly installments beginning April 1, 2026 (each RSU converts to one share when vested).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing timeliness: no late‑filing indication in the provided data.
Context
RSUs are a form of compensation that convert into common stock when they vest; they do not require the insider to pay cash at grant. This transaction is an equity award, not a purchase or sale, and should be viewed as a compensation-related grant rather than a direct market signal. Tax withholding or share retention rules may apply when the RSUs vest and are settled.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-17+167,005→ 3,422,243 total
Footnotes (1)
- [F1]Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.